ACP
ARRY

Acuta Capital Partners’s Array Biopharma Inc ARRY Stock Holding History

Acuta Capital Partners’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-480,020
Closed -$2.19M – 78
2015
Q3 		$2.19M Buy
+480,020
New +$2.85M 1.27% 30

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Acuta Capital Partners's ARRY Position: Q4 2015 in Review

Acuta Capital Partners sold out of Array Biopharma Inc (ARRY) in Q4 2015, closing a stake of 480,020 shares — an estimated $2.19M sold.

Acuta Capital Partners first reported a position in ARRY in Q3 2015 and held it in 1 quarter. The position peaked at $2.19M in Q3 2015. 151 funds tracked by Wall St. Rank hold ARRY as of Q4 2015.

  • Acuta Capital Partners reported no remaining Array Biopharma Inc position as of Q4 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 480,020 Array Biopharma Inc shares in Q4 2015, an estimated $2.19M.
  • Acuta Capital Partners first reported a position in Array Biopharma Inc in Q3 2015 and held it in 1 quarter.
  • Acuta Capital Partners's Array Biopharma Inc position peaked at $2.19M in Q3 2015.
  • 151 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2015.

Based on Acuta Capital Partners's 13F filing for Q4 2015, filed 12 Feb 2016.